OTCMKTS:PHMMF Pharma Mar (PHMMF) Stock Price, News & Analysis $92.57 0.00 (0.00%) As of 06/24/2025 Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartHeadlinesShort InterestBuy This Stock About Pharma Mar Stock (OTCMKTS:PHMMF) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Pharma Mar alerts:Sign Up Key Stats Today's Range$92.57▼$92.5750-Day Range$80.91▼$104.4952-Week Range$34.26▼$105.60Volume2,550 shsAverage Volume2,034 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingStrong Buy Company OverviewPharma Mar, S.A., a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles for the use in oncology in Spain, Italy, Germany, Ireland, France, rest of the European Union, the United States, and internationally. The company operates through Oncology and RNA Interference segments. It develops and commercializes Yondelis for the treatment of soft tissue sarcoma and for ovarian cancer; Aplidin for treating R/R multiple myeloma; and Zepzelca to treat patients with small cell lung cancer. The company develops Ecubectedin (PM14), which is in phase II clinical trials for the treatment of solid tumors, as well as in Phase I clinical trials for the treatment of soft tissue sarcoma and prostate cancer; PM534 that is Phase I clinical trials for treating solid tumors; PM54, which is in Phase I clinical trials for the treatment of solid tumors; SYL1801 that is in phase II clinical trials for treating macular degeneration; SYL116011, which is in preclinical studies for the treatment of ocular allergies; and SYL A and B that is in investigational studies to treat retinitis pigmentosa. In addition, it engages in the research, development, production, and sale of products with therapeutic activity based on reducing or silencing gene expression. Pharma Mar, S.A. was incorporated in 1986 and is based in Madrid, Spain.Read More… Receive PHMMF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Pharma Mar and its competitors with MarketBeat's FREE daily newsletter. Email Address PHMMF Stock News HeadlinesPharma Mar’s Strategic Shareholder MeetingJune 18, 2025 | tipranks.comExploring High Growth Tech Stocks In Europe May 2025May 16, 2025 | finance.yahoo.com3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are mere days away from a critical announcement from a key tech leader… One that will officially ignite “AI 2.0” – and potentially send a whole new class of stocks soaring. | Timothy Sykes (Ad)Exploring High Growth Tech Stocks in Europe April 2025April 14, 2025 | finance.yahoo.comPharma Mar’s Credit Rating Maintained at ‘BB+’April 4, 2025 | tipranks.comPharma Mar Implements Share Delivery Plan to Boost Employee EngagementApril 2, 2025 | tipranks.com3 European Growth Stocks With Insider Ownership Seeing Up To 52% Earnings GrowthMarch 27, 2025 | finance.yahoo.comPharma Mar Releases 2024 Director Remuneration ReportFebruary 28, 2025 | tipranks.comSee More Headlines PHMMF Stock Analysis - Frequently Asked Questions How have PHMMF shares performed this year? Pharma Mar's stock was trading at $81.07 at the beginning of 2025. Since then, PHMMF stock has increased by 14.2% and is now trading at $92.57. View the best growth stocks for 2025 here. How do I buy shares of Pharma Mar? Shares of PHMMF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Today6/25/2025Next Earnings (Estimated)7/28/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry MED - BIOMED/GENE Sub-IndustryN/A Current SymbolOTCMKTS:PHMMF Previous SymbolNASDAQ:PHMMF CIKN/A Webwww.pharmamar.com Phone(491) 846-6000Fax34-91-846-6001Employees509Year Founded1986Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio0.20 Current Ratio2.97 Quick Ratio2.33 Sales & Book Value Annual Sales$189.23 million Price / SalesN/A Cash Flow$0.41 per share Price / Cash Flow223.50 Book Value$11.62 per share Price / Book7.97Miscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable Beta0.22 Social Links Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report This page (OTCMKTS:PHMMF) was last updated on 6/26/2025 by MarketBeat.com Staff From Our PartnersPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredA grave, grave error.Famed financial analyst, Porter Stansberry, calls this technology “The Final Frontier” because it holds the ke...Porter & Company | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | Sponsored379 passengers walked away from thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pharma Mar Please log in to your account or sign up in order to add this asset to your watchlist. Share Pharma Mar With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.